CliffBio
small molecule

ESOMEPRAZOLE MAGNESIUM

ESOMEPRAZOLE MAGNESIUM

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameESOMEPRAZOLE MAGNESIUM
Active ingredientESOMEPRAZOLE MAGNESIUM
StrengthEQ 40MG BASE
Dosage formCAPSULE, DELAYED REL PELLETS
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2015
Marketing statusDISCN

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ESOMEPRAZOLE MAGNESIUM patent cliff — loss of exclusivity — | CliffBio